VXRT - Vaxart shows booster effect of vaccine platform with early-stage data for oral norovirus vaccine

Vaxart (NASDAQ:VXRT) has climbed ~11.8% in the pre-market after the company said its oral vaccine platform boosted the immune response in those who were vaccinated with its oral vaccine more than a year earlier. The results came from a Phase 1b study involving 12 subjects who were initially vaccinated with Vaxart's oral norovirus vaccine in late 2019. The individuals were again vaccinated between February and April 2021.   The immune responses to norovirus were similar between the seven participants who got the booster dose and those who did not receive the oral vaccine initially, the company said. In 29 days after the booster dose, serum IgG and IgA antibody responses were significantly elevated with no difference in titer between those who initially received the vaccine and subjects who did not receive the oral vaccine, according to Vaxart. Vaxart’s vaccine programs are based on an oral vaccine platform called VAAST. "We believe these results could

For further details see:

Vaxart shows booster effect of vaccine platform with early-stage data for oral norovirus vaccine